Measuring response in a post-RECIST world: from black and white to shades of grey

[1]  G. Rosner,et al.  Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Boris Freidlin,et al.  Design issues of randomized phase II trials and a proposal for phase II screening trials. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  G. Pond,et al.  Comparison of outcomes of phase II studies and subsequent randomized control studies using identical chemotherapeutic regimens. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  D. Gandara,et al.  Epidermal growth factor receptor tyrosine kinase inhibitors plus chemotherapy: case closed or is the jury still out? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  M. Ratain.  Phase II Oncology Trials: Let's Be Positive , 2005, Clinical Cancer Research.

[6]  R. Bukowski,et al.  Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC) , 2005 .

[7]  G. Rosner,et al.  Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Dirk Strumberg,et al.  Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Mark J Ratain,et al.  Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  G. Mack.  Genta sued over NDA withdrawal , 2004, Nature Biotechnology.

[11]  Thomas J Lynch,et al.  The phase III trial in the era of targeted therapy: unraveling the "go or no go" decision. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  S. George.  Selection bias, phase II trials, and the FDA accelerated approval process. , 2003, Journal of the National Cancer Institute.

[13]  L. Pelkmans,et al.  Insider information: what viruses tell us about endocytosis. , 2003, Current opinion in cell biology.

[14]  Seth M Steinberg,et al.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.

[15]  Gary L Rosner,et al.  Randomized discontinuation design: application to cytostatic antineoplastic agents. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  S. Wilhelm,et al.  BAY 43-9006: preclinical data. , 2002, Current pharmaceutical design.

[17]  E. Eisenhauer,et al.  Novel endpoints and design of early clinical trials. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  P. Therasse,et al.  Evaluation of response: new and standard criteria. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  W. Stadler.  New Trial Designs to Assess Antitumor and Antiproliferative Agents in Prostate Cancer , 2002, Investigational New Drugs.

[20]  R. Schilsky.  End points in cancer clinical trials and the drug approval process. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  J. Baselga.  The EGFR as a target for anticancer therapy--focus on cetuximab. , 2001, European journal of cancer.

[22]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[23]  M. Christian,et al.  Measuring response in solid tumors: unidimensional versus bidimensional measurement. , 1999, Journal of the National Cancer Institute.

[24]  Daniel,et al.  There are no bad anticancer agents, only bad clinical trial designs--twenty-first Richard and Hinda Rosenthal Foundation Award Lecture. , 1998 .

[25]  M J Ratain,et al.  Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents. , 1993, Journal of the National Cancer Institute.

[26]  Stephanie Green,et al.  Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria , 1992, Investigational New Drugs.

[27]  P. Lavin,et al.  Studies in variation associated with the measurement of solid tumors , 1980, Cancer.

[28]  J. Hanley,et al.  The effect of measuring error on the results of therapeutic trials in advanced cancer , 1976, Cancer.

[29]  T E Walsh,et al.  Reporting results. , 1969, Archives of otolaryngology.

[30]  J. Gurland,et al.  How reliable are tumor measurements? , 1965, JAMA.

[31]  A. Gilman,et al.  The initial clinical trial of nitrogen mustard. , 1963, American journal of surgery.

[32]  J. Wolff,et al.  Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. , 1948, The New England journal of medicine.

[33]  A. Satterfield,et al.  TREATMENT , 1924, California and western medicine.

[34]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[35]  I. Tannock,et al.  Reflections on medical oncology: an appeal for better clinical trials and improved reporting of their results. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  P. Lavin,et al.  An alternative model for the evaluation of antitumor activity. , 1981, Cancer clinical trials.

[37]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.

[38]  Lavin Pt,et al.  An alternative model for the evaluation of antitumor activity. , 1981 .

[39]  R. D. Hunter,et al.  WHO Handbook for Reporting Results of Cancer Treatment , 1980 .

[40]  Emil Frei,et al.  Appraisal of methods for the study of chemotherapy of cancer in man: Comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide , 1960 .